Keefe, Richard S.E.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 5,892

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity

Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 2,342

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

Keefe, R. (2004) · Schizophrenia Research

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 1,573

Persistent cannabis users show neuropsychological decline from childhood to midlife

Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S. E., McDonald, K., Ward, A., Poulton, R., & Moffitt, T. E. (2012) · Proceedings of the National Academy of Sciences

Cannabis and Cannabinoid ResearchSubstance Abuse Treatment and Outcomes

Cited by 1,523

Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria

Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 919

Schizophrenia Is a Cognitive Illness: Time for a Change in Focus

Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 825

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 744

Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 472

Barriers to Employment for People With Schizophrenia

Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J. K., Lieberman, J., & CATIE Study Investigators Group (2006) · American Journal of Psychiatry

Schizophrenia research and treatmentDisability Education and Employment

Cited by 465

How should DSM-V criteria for schizophrenia include cognitive impairment?

Keefe, R. S. E., & Fenton, W. S. (2007) · Schizophrenia Bulletin

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 394

A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial

Kollins, S. H., DeLoss, D. J., Cañadas, E., Lutz, J., Findling, R. L., Keefe, R. S. E., Epstein, J. N., Cutler, A. J., & Faraone, S. V. (2020) · The Lancet Digital Health

Attention Deficit Hyperactivity DisorderDigital Mental Health Interventions

Cited by 385

Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)

KEEFE, R., HARVEY, P., GOLDBERG, T., GOLD, J., WALKER, T., KENNEL, C., & HAWKINS, K. (2008) · Schizophrenia Research

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 342

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 314

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 307

The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study

Kern, R. S., Gold, J. M., Dickinson, D., Green, M. F., Nuechterlein, K. H., Baade, L. E., Keefe, R. S. E., Mesholam-Gately, R. I., Seidman, L. J., Lee, C., et al. (2011) · Schizophrenia Research

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 251

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial

Keefe, R. S. E., Fox, K. H., Harvey, P. D., Cucchiaro, J., Siu, C., & Loebel, A. (2011) · Schizophrenia Research

Schizophrenia research and treatmentPsychological Testing and Assessment

Cited by 237

A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

Krystal, A. D., Pizzagalli, D. A., Smoski, M., Mathew, S. J., Nurnberger, J., Lisanby, S. H., Iosifescu, D., Murrough, J. W., Yang, H., Weiner, R. D., et al. (2020) · Nature Medicine

Neuropeptides and Animal PhysiologyTreatment of Major Depression

Cited by 227

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 193

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 172

The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin

Schizophrenia research and treatmentStatistical Methods in Clinical Trials

Cited by 154

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 138

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia

McClay, J. L., Adkins, D. E., Åberg, K., Bukszár, J., Khachane, A. N., Keefe, R. S. E., Perkins, D. O., McEvoy, J. P., Stroup, T. S., Vann, R. E., et al. (2011) · Neuropsychopharmacology

Schizophrenia research and treatmentGenetic Associations and Epidemiology

Cited by 124

Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review

Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 107

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder

Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology

Treatment of Major DepressionAttention Deficit Hyperactivity Disorder

Cited by 74